Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
about
Targeting DNA Replication Stress for Cancer TherapyTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesUpdate on rational targeted therapy in AMLUbiquitylation, neddylation and the DNA damage responsePhase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinomaPharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivoPPARγ neddylation essential for adipogenesis is a potential target for treating obesity.A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.COP9 signalosome controls the degradation of cytosolic misfolded proteins and protects against cardiac proteotoxicity.Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.Inositol hexakisphosphate (IP6) generated by IP5K mediates cullin-COP9 signalosome interactions and CRL function.Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Blockage of neddylation modification stimulates tumor sphere formation in vitro and stem cell differentiation and wound healing in vivoNeddylation requires glycyl-tRNA synthetase to protect activated E2.Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo.Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function.Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1.MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcomaNEDD8 and HDACs: promising cotargets in AML.Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis.Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.Understanding drug-cytokine synergistic toxicity.Cullin E3 Ligase Activity Is Required for Myoblast Differentiation.Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides.The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.Inhibition of neddylation facilitates cell migration through enhanced phosphorylation of caveolin-1 in PC3 and U373MG cells.Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.
P2860
Q26739923-5817454D-DC85-4010-8A7C-EB0B1EF59598Q26752940-C1FA77A3-1498-438D-B3F6-D7BC7F68BE46Q26766152-9EE256AB-2D16-44EA-A21E-40307BB18DB2Q28087342-902457AB-4279-46CF-8E4C-D6FF46BBE9B6Q33427510-96E178C7-5D32-49D5-86C4-3DF30B6A397FQ33792598-50C76162-D5B5-47AE-B817-DE4488D6E2D9Q33912016-8113551C-4FAF-4BEC-B06F-43A9E4EB027BQ34476246-CBB28F3D-946D-4920-932D-8B899F7B550FQ34505392-8AFBCE4C-C223-473D-8F25-8A9DBA3CD566Q34518847-A1524B62-CC42-4960-8328-A616BDF34C5FQ34521260-A5C332AC-0507-4F14-AE2D-D9DB5E7450EAQ34543264-5AFBE6BF-BFD6-4D3A-BD47-BA4EBC6A88B2Q35363897-67AAD8BC-DB89-4D21-91B7-A668C1CCC5DAQ36259493-5552DA86-3F83-41DE-AC6B-823EEF8913DCQ36689799-F1D8B9E4-8BA1-4601-A288-421485657D86Q36770693-CB2A60B9-7F91-4149-8C80-57555C099AE2Q36785312-69B93B52-AC0F-4FF3-A7C3-BCC200DA1011Q36876973-BCDBBA91-3A8E-4B20-B651-B4044E517B66Q36957246-F6CFF4DD-B13F-465C-9AC8-F186EB4F731EQ37150065-ECE5FB83-679C-4089-B762-904F787D66F5Q37737112-A5315937-F2D0-42DA-B14B-DB7917EB668BQ38736706-6241AF0D-705B-4FFC-92E0-28E3246B4676Q38779048-1DCB09A3-27D5-4974-A445-9C4D10DCC191Q38797003-326B8038-B1B2-425A-8179-7900F6014D24Q38972048-9EF6D972-05E7-47E7-98AC-C17436C17E8CQ39175665-67489AB0-A531-4512-819E-ED260D1B7771Q39604750-68D71208-F682-431B-A686-E57A2713FA33Q40851893-7FCF762A-184C-448A-AB2E-8541E23764F4Q41107520-BA657316-334B-498D-9E17-5DDF8D283D36Q41843895-425C0642-A0EC-498B-B363-B9EA006533B1Q41849611-2B23229D-4289-48E5-BDAB-FB359B495A0FQ41991525-05105396-F8F6-491D-8F70-92FA789EB7E3Q42292376-4ED0F859-4BFE-408A-ADF6-A517A83F1721Q42361441-FCC1061B-224F-4F4C-9EAD-A4F8F2F0E933Q43142253-08A0BF0A-4A06-4F14-9609-646053F7D6B5Q45931257-56C8D486-1322-45B6-89F9-36A837067BEEQ47095447-BB618AF0-D537-406C-8879-4558377D2509Q47159993-7B6E9DEC-61E3-4084-9065-54CE1CF1BD25Q47174306-00D56A83-A29F-40D7-9465-84B98092FC3DQ47223079-408F0197-FD26-4BC6-95B3-13C775FED437
P2860
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@ast
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@en
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@nl
type
label
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@ast
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@en
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@nl
prefLabel
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@ast
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@en
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@nl
P2093
P2860
P356
P1476
Pevonedistat (MLN4924), a Firs ...... ic syndromes: a phase 1 study.
@en
P2093
Bruce J Dezube
Bruno C Medeiros
Dale L Bixby
Daniel J DeAngelo
Farhad Sedarati
Francis J Giles
Harry P Erba
Hélène Faessel
Jessica K Altman
Michael Maris
P2860
P304
P356
10.1111/BJH.13323
P407
P577
2015-03-02T00:00:00Z